Scientists discover control switch for immune system
controls immune system function. The research could lead to future
drug treatment advancements for rheumatoid arthritis, multiple
sclerosis and other autoimmune diseases.
By understanding this cellular process for turning off immune system activity, the hope is that this will lead to new treatments that will stop unwanted immune responses, such as those which occur in autoimmune diseases.
In autoimmune diseases, the immune system, which normally wards off invading viruses and bacteria, instead mistakenly attacks normal body tissues, leading to illness.
In the study, the team of scientists looked at two members of the herpes family of viruses, cytomegalovirus and herpes simplex virus, because of their ability to lay dormant in the immune system without causing disease.
"These viruses teach us how to manipulate the immune system," said La Jolla Institute for Allergy & Immunology (LIAI) scientist Carl Ware.
"We found that these two very different viruses were attacking the same communication pathway in the immune system. By disrupting that pathway, the viruses were keeping T lymphocytes - which are white blood cells that fight disease - from communicating with other cells in the immune system," he added.
Central in the viruses' ability to manipulate immune system communication was a cellular protein called the Herpes virus Entry Mediator (HVEM), which the scientists found effectively worked as an "off and on switch" for immune responses.
Several cellular proteins - members of the tumour necrosis factor (TNF) family - interact with HVEM to enable this immune system communication switch. HVEM is part of a larger TNF family of molecules involved in a wide variety of important immune system functions.
The finding is the latest from Ware's laboratory involving TNF receptors, which he has been studying for more than 20 years. Drugs targeted at the TNF family are prominent treatments against some autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease.
Mitchell Kronenberg, LIAI president and scientific director, said the scientific community regards the team's findings as very exciting. "This research could one day lead to the development of drugs that mimic the action of HVEM," he said. "That could give medical science a new method for reducing or even stopping the inflammation associated with rheumatoid arthritis and other autoimmune diseases."
The findings also have implications beyond autoimmune disease, including possible application in treatments for infectious diseases and cancer.
"An important part of our findings is that HVEM can not only switch off immune system response but it can also switch it on," Ware said.
"This may be valuable in fighting infectious disease, where the body needs a stronger immune response. It also could aid in prompting immune cells to attack cancerous cells."
The findings will be published September 13 in the Proceedings of the National Academy of Sciences (PNAS) in a paper entitled, "Evolutionarily Divergent Herpesviruses Modulate T cell activation by Targeting the Herpesvirus Entry Mediator (HVEM) Cosignaling Pathway."
